Tim Wilsdon is speaking during the conference in a session titled “Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements.”
For more information on this event, click here.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...